Steven C Moore1, Charles E Matthews1, Xiao Ou Shu1, Kai Yu1, Mitchell H Gail1, Xia Xu1, Bu-Tian Ji1, Wong-Ho Chow1, Qiuyin Cai1, Honglan Li1, Gong Yang1, David Ruggieri1, Jennifer Boyd-Morin1, Nathaniel Rothman1, Robert N Hoover1, Yu-Tang Gao1, Wei Zheng1, Regina G Ziegler1. 1. Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD (SCM, CEM, KY, MHG, BTJ, NR, RNH, RGZ); Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN (XOS, QC, GY, WZ); Frederick National Laboratory for Cancer Research, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick, MD (XX); Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China (HL, YTG); Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX (WHC); Information Management Services, Inc., Rockville, MD (DR, JBM).
Abstract
BACKGROUND: The role of estrogen metabolism in determining breast cancer risk and differences in breast cancer rates between high-incidence and low-incidence nations is poorly understood. METHODS: We measured urinary concentrations of estradiol and estrone (parent estrogens) and 13 estrogen metabolites formed by irreversible hydroxylation at the C-2, C-4, or C-16 positions of the steroid ring in a nested case-control study of 399 postmenopausal invasive breast cancer case participants and 399 matched control participants from the population-based Shanghai Women's Health Study cohort. Odds ratios (ORs) and 95% confidence intervals (CIs) of breast cancer by quartiles of metabolic pathway groups, pathway ratios, and individual estrogens/estrogen metabolites were estimated by multivariable conditional logistic regression. Urinary estrogen/estrogen metabolite measures were compared with those of postmenopausal non-hormone-using Asian Americans, a population with three-fold higher breast cancer incidence rates. All statistical tests were two-sided. RESULTS: Urinary concentrations of parent estrogens were strongly associated with breast cancer risk (ORQ4vsQ1 = 1.94, 95% CI = 1.21 to 3.12, Ptrend = .01). Of the pathway ratios, the 2-pathway:total estrogens/estrogen metabolites and 2-pathway:parent estrogens were inversely associated with risk (ORQ4vsQ1 = 0.57, 95% CI = 0.35 to 0.91, Ptrend = .03, and ORQ4vsQ1 = 0.61, 95% CI = 0.37 to 0.99, Ptrend = .04, respectively). After adjusting for parent estrogens, these associations remained clearly inverse but lost statistical significance (ORQ4vsQ1 = 0.65, 95% CI = 0.39 to 1.06, Ptrend = .12 and ORQ4vsQ1 = 0.76, 95% CI = 0.44 to 1.32, Ptrend = .28). The urinary concentration of all estrogens/estrogen metabolites combined in Asian American women was triple that in Shanghai women. CONCLUSIONS: Lower urinary parent estrogen concentrations and more extensive 2-hydroxylation were each associated with reduced postmenopausal breast cancer risk in a low-risk nation. Markedly higher total estrogen/estrogen metabolite concentrations in postmenopausal United States women (Asian Americans) than in Shanghai women may partly explain higher breast cancer rates in the United States. Published by Oxford University Press 2016. This work is written by US Government employees and is in the public domain in the United States.
BACKGROUND: The role of estrogen metabolism in determining breast cancer risk and differences in breast cancer rates between high-incidence and low-incidence nations is poorly understood. METHODS: We measured urinary concentrations of estradiol and estrone (parent estrogens) and 13 estrogen metabolites formed by irreversible hydroxylation at the C-2, C-4, or C-16 positions of the steroid ring in a nested case-control study of 399 postmenopausal invasive breast cancer case participants and 399 matched control participants from the population-based Shanghai Women's Health Study cohort. Odds ratios (ORs) and 95% confidence intervals (CIs) of breast cancer by quartiles of metabolic pathway groups, pathway ratios, and individual estrogens/estrogen metabolites were estimated by multivariable conditional logistic regression. Urinary estrogen/estrogen metabolite measures were compared with those of postmenopausal non-hormone-using Asian Americans, a population with three-fold higher breast cancer incidence rates. All statistical tests were two-sided. RESULTS: Urinary concentrations of parent estrogens were strongly associated with breast cancer risk (ORQ4vsQ1 = 1.94, 95% CI = 1.21 to 3.12, Ptrend = .01). Of the pathway ratios, the 2-pathway:total estrogens/estrogen metabolites and 2-pathway:parent estrogens were inversely associated with risk (ORQ4vsQ1 = 0.57, 95% CI = 0.35 to 0.91, Ptrend = .03, and ORQ4vsQ1 = 0.61, 95% CI = 0.37 to 0.99, Ptrend = .04, respectively). After adjusting for parent estrogens, these associations remained clearly inverse but lost statistical significance (ORQ4vsQ1 = 0.65, 95% CI = 0.39 to 1.06, Ptrend = .12 and ORQ4vsQ1 = 0.76, 95% CI = 0.44 to 1.32, Ptrend = .28). The urinary concentration of all estrogens/estrogen metabolites combined in Asian American women was triple that in Shanghai women. CONCLUSIONS: Lower urinary parent estrogen concentrations and more extensive 2-hydroxylation were each associated with reduced postmenopausal breast cancer risk in a low-risk nation. Markedly higher total estrogen/estrogen metabolite concentrations in postmenopausal United States women (Asian Americans) than in Shanghai women may partly explain higher breast cancer rates in the United States. Published by Oxford University Press 2016. This work is written by US Government employees and is in the public domain in the United States.
Authors: Barbara J Fuhrman; Catherine Schairer; Mitchell H Gail; Jennifer Boyd-Morin; Xia Xu; Laura Y Sue; Saundra S Buys; Claudine Isaacs; Larry K Keefer; Timothy D Veenstra; Christine D Berg; Robert N Hoover; Regina G Ziegler Journal: J Natl Cancer Inst Date: 2012-01-09 Impact factor: 13.506
Authors: Jane A Cauley; Joseph M Zmuda; Michelle E Danielson; Britt-Marie Ljung; Douglas C Bauer; Steven R Cummings; Lewis H Kuller Journal: Epidemiology Date: 2003-11 Impact factor: 4.822
Authors: A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Sonia M Boyapati; Xiao Ou Shu; Yu-Tang Gao; Qi Dai; Herbert Yu; J R Cheng; Fan Jin; Wei Zheng Journal: Cancer Causes Control Date: 2004-04 Impact factor: 2.506
Authors: T J Key; D Y Wang; J B Brown; C Hermon; D S Allen; J W Moore; R D Bulbrook; I S Fentiman; M C Pike Journal: Br J Cancer Date: 1996-06 Impact factor: 7.640
Authors: N C Onland-Moret; R Kaaks; P A H van Noord; S Rinaldi; T Key; D E Grobbee; P H M Peeters Journal: Br J Cancer Date: 2003-05-06 Impact factor: 7.640
Authors: Joshua N Sampson; Roni T Falk; Catherine Schairer; Steven C Moore; Barbara J Fuhrman; Cher M Dallal; Douglas C Bauer; Joanne F Dorgan; Xiao-Ou Shu; Wei Zheng; Louise A Brinton; Mitchell H Gail; Regina G Ziegler; Xia Xu; Robert N Hoover; Gretchen L Gierach Journal: Cancer Res Date: 2016-12-23 Impact factor: 12.701
Authors: Steven C Moore; Mary C Playdon; Joshua N Sampson; Robert N Hoover; Britton Trabert; Charles E Matthews; Regina G Ziegler Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Sangmi Kim; Jeff Campbell; Wonsuk Yoo; Jack A Taylor; Dale P Sandler Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-11-18 Impact factor: 4.254
Authors: Lancia N F Darville; Jayden K Cline; Carrie Rozmeski; Yessica C Martinez; Shannan Rich; Steven A Eschrich; Kathleen M Egan; Lusine Yaghjyan; John M Koomen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2020-07-29 Impact factor: 3.205
Authors: Zhikai Zhu; Yingxi Chen; Jiansong Ren; Sanford M Dawsey; Jian Yin; Neal D Freedman; Jin-Hu Fan; Philip R Taylor; Yuanli Liu; You-Lin Qiao; Christian C Abnet Journal: Cancer Prev Res (Phila) Date: 2021-03-25